NDAORALTABLET
Approved
Jan 2012
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
INLYTA (axitinib) by Pfizer is receptor tyrosine kinase inhibitors [moa]. Approved for renal cell carcinoma. First approved in 2012.
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INLYTA (axitinib) is an oral receptor tyrosine kinase inhibitor developed by Pfizer and approved in January 2012 for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy. The drug works by inhibiting multiple kinase pathways critical to tumor angiogenesis and cell proliferation. INLYTA is positioned as a second-line targeted therapy option in the RCC treatment landscape, competing against both older kinase inhibitors and newer immunotherapy-based combinations.
$0.5BPart D
11.2 years to LOEMechanism of Action
Receptor Tyrosine Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Indications (1)
Clinical Trials (20)
Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study
Started Apr 2026
850 enrolled
Neovascular Age-Related Macular Degeneration (nAMD)
A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
Started Nov 2025
25 enrolled
Metastatic Renal Cell CarcinomaMetastatic Renal CancerRenal Cell Carcinoma+3 more
Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
Started Sep 2025
30 enrolled
Advanced Renal Cell Carcinoma (aRCC)
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
Started Nov 2024
825 enrolled
Neovascular Age-related Macular Degeneration
Avelumab, Palbociclib and Axitinib in Advanced RCC
Started May 2024
0Advanced Clear Cell Renal Cell Carcinoma
Worked on INLYTA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.